Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 15/20 | 0.51 |
| ▸ | CTSB | P07858 | 11/20 | 0.51 |
| ▸ | CTSL | P07711 | 10/20 | 0.51 |
| ▸ | CTSS | P25774 | 7/20 | 0.51 |
| ▸ | CTSF | Q9UBX1 | 6/20 | 0.51 |
| ▸ | CTSV | O60911 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14673428 | 0.94 | CTSK (0.47) | CTSKCTSBCTSLCTSSCTSF | |
| SCHEMBL2155858 | 0.89 | CTSK (0.43) | CTSKCTSBCTSLCTSSCTSF | |
| SCHEMBL2157640 | 0.89 | CTSK (0.51) | CTSKCTSBCTSLCTSSCTSF | |
| SCHEMBL5742251 | 0.89 | CTSK (0.48) | CTSKCTSBCTSLCTSSCTSF | |
| SCHEMBL2155942 | 0.82 | CTSK (0.48) | CTSKCTSBCTSLCTSSCTSF | |
| SCHEMBL14874955 | 0.82 | CTSB (0.51) | CTSKCTSBCTSLCTSSCTSF | |
| SCHEMBL2155897 | 0.82 | CTSK (0.43) | CTSKCTSBCTSLCTSSCTSF | |
| SCHEMBL2155352 | 0.81 | CTSK (0.41) | CTSKCTSBCTSLCTSSCTSF | |
| SCHEMBL14673261 | 0.81 | CTSK (0.39) | CTSKCTSBCTSLCTSSCTSF | |
| SCHEMBL2437963 | 0.81 | CTSK (0.43) | CTSKCTSBCTSLCTSSCTSF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270555-A1 | ORGANIC COMPOSITIONS TO TREAT BETA-CATENIN-RELATED DISEASES | ARROWHEAD PHARMACEUTICALS INC (US) | 2025-08-28 | — | — | US | disclosed |
| US-12264167-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-12209098-B2 | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2025-01-28 | — | — | US | disclosed |
| US-20240199609-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2024-06-20 | — | — | US | disclosed |
| US-11952386-B2 | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2024-04-09 | — | — | US | disclosed |
| US-11905283-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2024-02-20 | — | — | US | disclosed |
| WO-2023240024-A1 | SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| EP-4282416-A2 | PROCESS OF MANUFACTURE OF A COMPOUND FOR INHIBITING THE ACTIVITY OF SHP2 | Novartis AG (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-20230338587-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | NOVARTIS PHARMA AG (CH) | 2023-10-26 | — | — | US | disclosed |
| US-20230321285-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | NOVARTIS AG (CH) | 2023-10-12 | — | — | US | disclosed |
| WO-2015107494-A1 | 1 -(TRIAZIN-3-YI_/PYRIDAZIN-3-YL)-PIPER(-AZINE)IDINE DERIVATIVES AND COMPOSITIONS THEREOF FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2015-07-23 | — | — | WO | disclosed |
| US-20140336503-A1 | RADIOLABELED BIOMARKERS FOR OSTEOCLAST ACTIVATION AND RELATED METHODS THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-11-13 | — | — | US | disclosed |
| US-8877801-B2 | Compounds and compositions as selective estrogen receptor degraders | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| US-20140235660-A1 | COMPOUNDS AND COMPOSITIONS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NOVARTIS AG (CH) | 2014-08-21 | — | — | US | disclosed |
| US-8772336-B2 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2014-07-08 | — | — | US | disclosed |
| EP-2144871-B1 | AMIDATION PROCESS FOR THE PREPARATION OF CATHEPSIN K INHIBITORS | MERCK CANADA INC (CA) | 2014-06-25 | — | — | EP | disclosed |
| US-20130331597-A1 | AMIDATION PROCESS | MERCK SHARP & DOHME CORP. | 2013-12-12 | — | — | US | disclosed |
| US-20130035312-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBIORS | AXYS PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-8273913-B2 | Amidation process for the preparation of cathepsin K inhibitors | MERCK CANADA INC. (CA) | 2012-09-25 | — | — | US | disclosed |
| US-20100130782-A1 | AMIDATION PROCESS FOR THE PREPARATION OF CATHEPSIN K INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035312-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBIORS | CTSB, CTSS, CTSZ | CTSK 4/4885CTSB 1/4885CTSL 8/4885 |
| US-11952386-B2 | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | PTPN5, PTPN1, PTPN7 | CTSK 3656/4885CTSB 2794/4885CTSL 4716/4885 |
| US-20230321285-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | IL15RA, IL15, CD274 | CTSK 1017/4885CTSB 1210/4885CTSL 699/4885 |
| US-11905283-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN1, PTPN2, PTPN5 | CTSK 4062/4885CTSB 3409/4885CTSL 4653/4885 |
| US-20140235660-A1 | COMPOUNDS AND COMPOSITIONS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESR2 | CTSK 1475/4885CTSB 914/4885CTSL 2331/4885 |
| US-20140336503-A1 | RADIOLABELED BIOMARKERS FOR OSTEOCLAST ACTIVATION AND RELATED METHODS THEREOF | CTSK, CTSF, CTSB | CTSK 1/4885CTSB 3/4885CTSL 11/4885 |
| US-12264167-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors | SRC, PTPRCAP, PTPRC | CTSK 2815/4885CTSB 3133/4885CTSL 4138/4885 |
| US-12209098-B2 | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | PTPN5, PTPN1, PTPN7 | CTSK 3656/4885CTSB 2794/4885CTSL 4716/4885 |
| US-20130331597-A1 | AMIDATION PROCESS | PAM, AFF4, PFAS | CTSK 2364/4885CTSB 2056/4885CTSL 3230/4885 |
| US-20100130782-A1 | AMIDATION PROCESS FOR THE PREPARATION OF CATHEPSIN K INHIBITORS | CTSK, CTSB, CTSF | CTSK 1/4885CTSB 2/4885CTSL 11/4885 |
| US-20240199609-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN2, PTPN5 | CTSK 4062/4885CTSB 3409/4885CTSL 4653/4885 |
| US-20230338587-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | IL15RA, CD274, IL15 | CTSK 1049/4885CTSB 1317/4885CTSL 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.